Vanguard Global Advisers
KPRX icon

Vanguard Global Advisers’s Kiora Pharmaceuticals KPRX Stock Holding History

Vanguard Global Advisers’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$386 – 3697
2026
Q1 		$386 Buy
+200
New +$422 ﹤0.01% 3663

Other funds holding KPRX

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Global Advisers's KPRX Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Kiora Pharmaceuticals (KPRX) in Q2 2026, closing a stake of 200 shares — an estimated $386 sold.

Vanguard Global Advisers first reported a position in KPRX in Q1 2026 and held it in 1 quarter. The position peaked at $386 in Q1 2026. 19 funds tracked by Wall St. Rank hold KPRX as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Kiora Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 200 Kiora Pharmaceuticals shares in Q2 2026, an estimated $386.
  • Vanguard Global Advisers first reported a position in Kiora Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Kiora Pharmaceuticals position peaked at $386 in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.